RxDoctor Payments DataLook up a doctor →

Marina Plon, MD

Interventional Cardiology · Las Vegas, NVNPI 1366531667

Payments from drug & device makers

$11,506in general payments, 2019–2025

Across 439 payments — averaging $26.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Novartis$1K
  • Merck$917
  • Actelion Pharmaceuticals US, Inc.$833
  • Medtronic$672
  • Bayer$518
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$11,13897%
  • Education$3683%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,506 in reported general payments places this provider in the 55th percentile of 62 interventional cardiology providers in Nevada.

See all interventional cardiology providers in Nevada

Medicare billing

Part B allowed, 2024
$480,578
Medicare patients
413
Services billed
12,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$144,908
EntrestoSacubitril/Valsartan86$114,056
JardianceEmpagliflozin49$79,950
FarxigaDapagliflozin Propanediol64$74,671
OzempicSemaglutide54$63,608
Repatha SureclickEvolocumab65$48,989
TradjentaLinagliptin36$45,506
RybelsusSemaglutide15$31,616
MultaqDronedarone Hcl18$29,097
BrilintaTicagrelor25$25,337
XareltoRivaroxaban15$23,097
TrulicityDulaglutide11$18,136
VerquvoVericiguat13$15,388
Pitavastatin Calcium21$11,281
VascepaIcosapent Ethyl25$11,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$326$144,908133 claims
Boehringer IngelheimJardiance, Tradjenta$268$125,45685 claims
NovartisEntresto$1,450$114,05686 claims
AstraZenecaFarxiga, Brilinta$252$100,00989 claims
Novo NordiskOzempic, Rybelsus$372$95,22469 claims
Sanofi-aventis U.S. LLCMultaq$151$29,09718 claims
Johnson & JohnsonXarelto$295$23,09715 claims
MerckVerquvo$917$15,38813 claims
AbbVieSynthroid$11$1,68623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 62 interventional cardiology providers in Nevada.

Other interventional cardiology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →